The Pharmaceutical Journal
Vol 280 No 7499 p496
26 April 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

NICE rejects abatacept for RA

The National Institute for Health and Clinical Excellence has rejected abatacept (Orencia) for the treatment of rheumatoid arthritis, despite an appeal by the product’s manufacturer.

In addition, NICE has decided that infliximab (Remicade) should not be used to treat subacute moderate to severe active ulcerative colitis.